A hospital on Long Island is one of three sites nationally spearheading clinical trials for an experimental nasal COVID-19 vaccine. This vaccine could potentially diminish disease transmission and infection rates, offering fresh hope in the ongoing pandemic. The trials are taking place at NYU Langone Hospital-Long Island in Mineola, which is actively recruiting eligible adults aged between 18 and 64. The National Institutes of Health sponsors this promising initiative. If approved, this nasal vaccine may draw people who have been otherwise reluctant to take the COVID-19 shot.
According to Dr. MartÃn Bäcker, the vaccine center’s associate director at the Long Island hospital, the nasal vaccine kindles our immune response right at the infection site, potentially preventing milder infections and transmissions more effectively than the existing vaccines. As the summer COVID-19 surge heightens, cases, emergency room visits, and hospitalizations are on an upward trajectory, according to data from the Centers for Disease Control and Prevention. Long Island alone has experienced an increase in hospitalizations from 192 to 217 within a week. Many of these cases seem to be relatively mild infections, which the nasal vaccine aims to combat.
Dr. Jeanne Marrazzo, the NIH’s National Institute of Allergy and Infectious Diseases director, states that first-generation COVID-19 vaccines remain successful in preventing severe illness, hospitalizations, and death. However, their ability to prevent infection and milder forms of disease is limited. As new virus variants continue to emerge, there is a profound need for next-gen COVID-19 vaccines, including nasal vaccines that could potentially lower SARS-CoV-2 infections and transmission rates.
Initial animal tests have revealed that the vaccine induces a robust systemic immune response, marking the first-time people will be tested. Approximately 60 participants across all three trial sites will be included in the study. The additional locations are Baylor College of Medicine in Houston and The Hope Clinic of Emory University in Georgia. To qualify, participants need to have received a minimum of three doses of the COVID-19 vaccine. The first group of volunteers will be administered a low nasal spray dose. Based on safety and tolerability, subsequent groups will receive progressively higher doses. Over the coming year, subjects’ immune response will be evaluated multiple times through blood and nasal measurements. The goal is to assess safety and immune activation.
The new option spurs hopes of increased vaccination rates among the populace. For further details regarding participation in the study, individuals can contact the hospital via phone or email. Volunteers play a critical role in advancing medicine and healthcare by supporting such studies.
Source: https://www.newsday.com/news/health/coronavirus/nasal-covid-vaccine-trials-hdk3ukkr